Abstract
Optimal identification of the risk of developing cardiotoxicity upon trastuzumab (TZM) treatment appears necessary as this risk may impair treatment compliance and compromise long-term recovery. To better understand and predict cardiac toxicity, the molecular mechanisms underlying this phenomenon need to be known. HER2 is present at the cell surface of cardiomyocytes. Neuregulin is produced by cardiac endothelial cells and binds to HER4, thus leading to dimerization with HER2 and subsequent cell signaling necessary for normal cardiac function. Decreasing HER2 activity has a major impact on cardiomyocyte function. However, the precise molecular mechanisms responsible for TZM-induced cardiac dysfunction are still unclear. This mini-review aims to summarize genetic, pharmacological and medical data helping to identify mechanisms that could explain cardiotoxicity. Of potential interest, these mechanisms highlight the importance of HER2 genetic polymorphism (Val655Ile) in the identification of patients at risk of developing TZMinduced cardiac effects.
Keywords: Cardiotoxicity, genetic polymorphism, HER2, personalized treatment, trastuzumab.
Current Drug Targets
Title:Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Volume: 15 Issue: 13
Author(s): Gerard A. Milano, Emilie Serres, Jean-Marc Ferrero and Joseph Ciccolini
Affiliation:
Keywords: Cardiotoxicity, genetic polymorphism, HER2, personalized treatment, trastuzumab.
Abstract: Optimal identification of the risk of developing cardiotoxicity upon trastuzumab (TZM) treatment appears necessary as this risk may impair treatment compliance and compromise long-term recovery. To better understand and predict cardiac toxicity, the molecular mechanisms underlying this phenomenon need to be known. HER2 is present at the cell surface of cardiomyocytes. Neuregulin is produced by cardiac endothelial cells and binds to HER4, thus leading to dimerization with HER2 and subsequent cell signaling necessary for normal cardiac function. Decreasing HER2 activity has a major impact on cardiomyocyte function. However, the precise molecular mechanisms responsible for TZM-induced cardiac dysfunction are still unclear. This mini-review aims to summarize genetic, pharmacological and medical data helping to identify mechanisms that could explain cardiotoxicity. Of potential interest, these mechanisms highlight the importance of HER2 genetic polymorphism (Val655Ile) in the identification of patients at risk of developing TZMinduced cardiac effects.
Export Options
About this article
Cite this article as:
Milano A. Gerard, Serres Emilie, Ferrero Jean-Marc and Ciccolini Joseph, Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?, Current Drug Targets 2014; 15 (13) . https://dx.doi.org/10.2174/1389450115666141114151911
DOI https://dx.doi.org/10.2174/1389450115666141114151911 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
Emerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Progress in Drug Delivery, Therapeutic Strategies, and Nursing Practices: Enhancing Diagnostics and Clinical Outcomes in Complex Diseases
The recent advancements in drug delivery systems as well as therapeutics have significantly improved therapy effectiveness combined with better patient results specifically for difficult disease management. The modern pharmaceutical research field makes drug targeting its main priority because this approach strengthens therapeutic agents' precision while improving their effectiveness. Multiple delivery ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnostic Value of HLA Typing in Pathogenesis of Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Propranolol Safety Profile in Children
Current Drug Safety Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science Editorial (Thematic Issue: The Acute Management of Pediatric Heart Failure)
Current Cardiology Reviews Transition of Care for Patients with Diabetes
Current Diabetes Reviews The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer
Clinical Cancer Drugs Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia
Drug Metabolism Letters The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design B Vitamins as Adjunctive Treatment for Chronic Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Classification of Heart Disease Using MFO Based Neural Network on MRI Images
Current Medical Imaging Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Chemokine Receptor CCR5 Antagonist Maraviroc: Medicinal Chemistry and Clinical Applications
Current Topics in Medicinal Chemistry Subject Index To Volume 2
Current Cardiology Reviews Common Variants for Heart Failure
Current Genomics Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry Mitochondrial Oxidative Stress and Heart Failure ∼Novel Pathophysiological Insight and Treatment Strategies∼
Current Cardiology Reviews Modulation of the Rho/ROCK Pathway in Heart and Lung after Thorax Irradiation Reveals Targets to Improve Normal Tissue Toxicity
Current Drug Targets Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery